[Statins: for the time being, do not as a rule prescribe the maximum dose]

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Statins are proven to reduce cardiovascular disease (CVD) risk and mortality.
• The optimal dosage of statin therapy remains a subject of debate.
• High-dose statins offer greater LDL-cholesterol reduction, but their impact on morbidity and mortality compared to lower doses is unclear.

Purpose of the Study:

• To evaluate the efficacy and safety of high-dose versus low-dose statin therapy in patients with existing cardiovascular disease.
• To determine if higher statin doses provide additional benefits in reducing cardiovascular events and overall mortality.

Main Methods:

• Analysis of two large clinical trials, focusing on the 'Treat to New Targets' trial.
• Comparison of high-dose atorvastatin (80 mg) versus low-dose atorvastatin (10 mg) in patients with pre-lowered LDL-cholesterol levels.
• Assessment of cardiovascular events, LDL-cholesterol levels, and overall mortality, including noncardiac causes.

Main Results:

• High-dose atorvastatin (80 mg) significantly reduced cardiovascular events compared to low-dose atorvastatin (10 mg) in patients with LDL-cholesterol ≤ 3.4 mmol/l.
• No significant difference in overall mortality was observed between the high-dose and low-dose groups.
• Increased noncardiac mortality was noted in the high-dose atorvastatin group, raising safety concerns.

Conclusions:

• High-dose statin therapy demonstrates superior efficacy in reducing cardiovascular events but does not improve overall survival.
• The potential for increased noncardiac mortality necessitates careful consideration of high-dose statin indications.
• Current evidence suggests reserving high-dose statins for patients at very high cardiovascular risk, such as those with recurrent events.